The consequences of blood donations infected with human immunodeficien
cy virus the rapid advances in protein fractionation and the introduct
ion of recombinant DNA technology have revolutionized the range of pla
sma products available to the clinician. This article reviews these de
velopments and describes recent recommendations on their use.